Published
The committee will discuss new drug application 215484, for the Nrf2 activator, bardoxolone methyl capsules, submitted by Reata Pharmaceuticals, Inc. The proposed indication is to slow the progression of chronic kidney disease caused by Alport syndrome in patients 12 years of age and older.
- Category
- Management
Be the first to comment
-
8:34:46
March 5, 2024 Meeting of the Medical Imaging Drugs Advisory Committee (MIDAC)
-
6:04:50
Oncologic Drugs Advisory Committee Meeting
-
6:49:31
April 12, 2024 Meeting of the Oncologic Drugs Advisory Committee (ODAC)
-
2:49:56
2024 06 06 Investor Advisory Committee Meeting Public Meeting Part 02
-
3:54:24
May 3rd meeting of the Advisory Committee to the Director (ACD)
-
1:04:17
Business Management Advisory Committee Meeting
-
7:33:16
May 24, 2024 Endocrinologic and Metabolic Drugs Advisory Committee (EMDAC) Meeting
-
9:05:10
October 31, 2024 Endocrinologic and Metabolic Drugs Advisory Committee
-
2:16:12
Budget Advisory Committee Meeting, February 28, 2023
-
9:08:15
March 15, 2024 Meeting of the Oncologic Drugs Advisory Committee (ODAC)
-
03:29
Deca Roleplay Video - Lily Papadakis (Marshall) (Business Management)
-
00:20
motivational video for libasna ll inspiration for upsc aspirants ll #short #upse #amitabhbachchan
-
17:46
FreeStyle Libre 3 vs Dexcom G6 | Full Test & Review
-
09:59
Learn Communication Skills | English Speaking | Management Insight #7
-
1:43:58
How to Trade In Stocks By: Jesse Livermore. Complete Audiobook.
-
06:52
Three Questions to Ask Yourself To Be a Great Leader
-
07:35
find your unique style | Style Roots QUIZ + body types
